Quantum BioPharma Ltd., a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, has announced significant corporate updates involving equity incentives and debt management.
The company granted 60,000 restricted share units (RSUs) under its equity incentive plan, with these units subject to specific vesting criteria. Simultaneously, the board of directors approved settling outstanding debt to independent parties by issuing Class B Shares at a deemed price of US$6.75 per share.
Through its subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma continues to advance research on Lucid-MS, a patented compound designed to prevent and reverse myelin degradation in preclinical multiple sclerosis models. The company has also maintained strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc.
A notable aspect of Quantum BioPharma’s portfolio includes its involvement with [Celly Nutrition Corp.](https://www.unbuzzd.com), where the company retains a 25.71% ownership stake. The agreement includes royalty provisions, with potential payments of up to 7% of sales from the UNBUZZD product, transitioning to 3% after reaching $250 million in total payments.
These corporate actions reflect Quantum BioPharma’s ongoing commitment to developing innovative biotech solutions and managing its financial resources strategically.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Grants Restricted Share Units and Settles Outstanding Debt.